Mesalamine premix-based delayed release formulation and its efficacy assessment using a 3D in-vitro gut model for inflammatory bowel disease

Key Points

• Efficacy assessment shows significant potential for mesalamine in treating inflammatory bowel disease with a 3D in-vitro gut model.
• In the study, the 3D gut model showed improved drug delivery properties compared to conventional methods.
• Formulation included a mesalamine premix designed for delayed release to enhance therapeutic effects.
• Findings suggest that using advanced in-vitro models may better predict clinical outcomes in drug development.